跳至主要内容
临床试验/CTRI/2019/06/019734
CTRI/2019/06/019734尚未招募不适用

Comparison of Unani formulations Zuroor-e-Qula and Jawarish Amla sada with allopathic antioxidants in management of patients with early-intermediate stage oral submucous fibrosis

Ministry of AYUSH1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2019年1月7日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
120
试验地点
1
主要终点
a)Inter-incisal mouth opening

研究概览

简要总结

Oralsubmucous ï¬brosis (OSMF) is a chronic, insidious disease that is associatedwith signiï¬cant functional morbidity and an increased risk for malignancy. Itprimarily occurs due to areca nut chewing and is characterized by restrictedmouth opening, burning sensation on having hot and spicy food and stiffness andblanching of the oral mucosa. OSMF predominantly affects South Asian and East Asian populations. OSMF isthe major health issue affecting 14 million Indian population. Themalignant transformation rate of OSMF in India has been reported to as high as27% over many years.

Treatmentof OSMF is a challenge. A wide range of treatment including drug management,surgical therapy, and physiotherapy have been attempted till date, with varyingdegrees of benefit, but none have been able to cure this disease. Severalcomplementary and alternative medicines have been evaluated in OSMF patientslike curcumin, aloe vera, spirullina, allicin  andpapain. Anti-oxidants like lycopene obtained from tomato extract andherbal anti-oxidants like oxitard are found to be effective in the managementof OSMF.

Theclassical literature of Unani System of Medicine has a large number offormulations which have been used in various diseases of oral cavity. All theimportant books such as KitÄb al-HÄw**Ä« fi’l-Tibb byMuhammad b. Zakariyya RÄzÄ« (d. 926),al-Mu‘ÄlajÄt al-BuqrÄtiyya byAbÅ« HasanAhmad b. Muhammad TabarÄ«(d. 985), KÄmil al-SanÄ‘a al-Tibbiyyaby ‘AlÄ« b. ‘AbbÄs MajÅ«sÄ« (d. 994),Ghin**Ä MunÄby AbÅ« MansÅ«r Hasan QamrÄ« (d. 999)*,al-QÄnÅ«*n fi’l-Tibb byIbn SÄ«nÄ (d. 1037), al-MÅ«jaz fi’l-Tibbby Ibn NafÄ«s QarshÄ« (d. 1288), KitÄb al-TaysÄ«r fi’l-MadÄwa wa-al-Tadb**Ä«**rby Ibn Zuhr (d.1162), KitÄbal-MukhtÄrÄt fi’l-Tibbby Ibn Hubal (d. 1213), Sharahal-Asb**Äb wa-al-‘AlÄmÄt by NafÄ«s b. ‘Iwaz (d. 1439),  MÄ«zÄnal-Tibb by Akbar ArzÄnÄ« (d. 1721), Iks**Ä«r-i A‘zam byMuhammad A‘zam KhÄn (d. 1902) have exclusive chapters on thediseases of oral cavity.

Formulationsmentioned in different formularies and pharmacopoeias of Unani System ofMedicine have never been tried in OSMF patients. The formulationsdiscussed/mentioned under the heading of Qulđ(Stomatitis)have many ingredients which may be useful in OSMF patients. Secondly, theantioxidants have been found to be beneficial in the cases of OSMF and variousstudies have reported the benefits of these agents in OSMF. Many single andcompound drugs mentioned in the Unani classics have many ingredients which havebeen shown to possess antioxidant activity and may be useful in OSMF. The individual constituents of the presentformulations have also been reported to be safe (18). The current studystems from lacunae in the routine usage of unani formulations for thisdebilitating oral disorder. Therefore, it was hypothesized that unaniformulations could be effective in patients with OSMF due to theiranti-inflammatory, potent anti-oxidant and anti-carcinogenic properties. Inthis study, we propose to evaluate the efficacy and safety of Unani drugs Zuroor-e-Qula and Jawarish Amla sada in the management of early and intermediatestage OSMF.

研究设计

研究类型
Interventional
分配方式
Random Number Table
盲法
Outcome Assessor Blinded

入排标准

年龄范围
15.00 Year(s) 至 90.00 Year(s)(—)
性别
All

入选标准

  • i.Patients with current or previous use of any form of smokeless tobacco and/or areca nut (any duration and frequency) ii.Patients having early-intermediate stage OSMF designated as Grade I and II by the grading system proposed by Kerr et al (29).
  • iii.Patients willing to quit the habit of smokeless tobacco and/or areca nut.
  • iv.Patients willing to accept regular follow-up protocol.

排除标准

  • i.Patients having advanced stage OSMF designated as Grade III, IV or V by the grading system proposed by Kerr et al.
  • ii.Any significant medical condition such as scleroderma, anemic stomatitis and diabetes that would interfere with the safety, treatment or compliance with the protocol.
  • Known diabetics or those with altered blood sugar values at the baseline assessment will be excluded from the study.
  • iii.Patients with known allergy or contra-indication to any of the ingredients of the test drugs.
  • iv.Patients already undergoing treatment for OSMF.
  • v.Pregnant and lactating females.
  • vi.Patients having concomitant pericoronitis or any other dental condition leading to trismus.

结局指标

主要结局

a)Inter-incisal mouth opening

时间窗: every 2 weeks for 3 months:

b)Tongue protrusion

时间窗: every 2 weeks for 3 months:

c)Range of jaw movements

时间窗: every 2 weeks for 3 months:

d) Burning sensation/pain

时间窗: every 2 weeks for 3 months:

次要结局

  • a)Adverse events or side effects reported after taking the Unani formulations.(b)The impact of OSMF on quality of life of the patients will be assessed.)

研究者

申办方类型
Government funding agency

研究点 (1)

Loading locations...

相似试验